D-penicillamine and gold salt treatments were complicated by myasthenia and pemphigus, respectively, in the same patient with rheumatoid arthritis

A 53-year-old woman with rheumatoid arthritis developed myasthenia gravis after 6 months of therapy with D-penicillamine. Nineteen months after D-penicillamine was discontinued and 12 months after the beginning of gold therapy, she developed pemphigus vulgaris. This is the first reported case of gol...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology international 1995-09, Vol.15 (3), p.95-97
Main Authors: CIOMPI, M. L, MARCHETTI, G, BAZZICHI, L, PUCCETTI, L, AGELLI, M
Format: Article
Language:English
Subjects:
Antirheumatic Agents - adverse effects
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - immunology
Biological and medical sciences
Drug toxicity and drugs side effects treatment
Female
Humans
Immunocompromised Host
Medical sciences
Middle Aged
Myasthenia Gravis - chemically induced
Organogold Compounds
Pemphigus - chemically induced
Penicillamine - adverse effects
Pharmacology. Drug treatments
Toxicity: blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 53-year-old woman with rheumatoid arthritis developed myasthenia gravis after 6 months of therapy with D-penicillamine. Nineteen months after D-penicillamine was discontinued and 12 months after the beginning of gold therapy, she developed pemphigus vulgaris. This is the first reported case of gold-induced pemphigus in rheumatoid arthritis. This study further underlines the complex interactions between the effects of treatment with sulfhydryl-disulfide exchange drugs and the altered immunological system of patients affected by rheumatoid arthritis.
ISSN:0172-8172
1437-160X
DOI:10.1007/BF00302124